Dr. Timothy Francis Cloughesy, MD

Dr. Cloughesy practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Dr. Cloughesy's NPI, 1154356053, was assigned on July 11, 2006. Dr. Cloughesy graduated from Tulane School of Medicine in 1987. Dr. Cloughesy holds California license G63435.

Dr. Cloughesy's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Dr. Cloughesy's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Dr. Cloughesy is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Cloughesy to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cloughesy practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Cloughesy's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Cloughesy is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Cloughesy is licensed in California.

Dmand AI lists epilepsy among the conditions Dr. Cloughesy treats.

CMS data shows 224 Medicare services from Dr. Cloughesy across 2 procedure codes in 2024, all of them office visits, for 96 Medicare patients. Medicare paid $27,252 for them.

CMS counts 96 Medicare patients who saw Dr. Cloughesy in 2024. The largest group is 65 to 74, with 44 patients. 63% of them have high cholesterol, and 54% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.48, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cloughesy's median patient age at 53, with 47% women.

In 2024, Dr. Cloughesy wrote 33 Medicare Part D claims for 11 patients. 67% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $371,114 in total drug cost. In 2023, CMS named 23 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Cloughesy for performance year 2024, reported as part of a group. Dr. Cloughesy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cloughesy as offering telehealth.

Dmand AI links 62 papers to Dr. Cloughesy, published from 2011 to 2025. 2013 was the busiest year, with 16. The most frequent topics are Glioma. Dr. Cloughesy's most frequent co-authors are Mark Raymond Gilbert, MD, Susan M. Chang, MD and Minesh P. Mehta, MD.

Dmand AI links Dr. Cloughesy to 20 clinical trials, 7 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Astrocytoma. Jonsson Comprehensive Cancer Center sponsors the most, 7. Open Payments lists research payments to Dr. Cloughesy that name 1 trial.

CMS Open Payments shows 208 general payments to Dr. Cloughesy from 28 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Servier Pharmaceuticals LLC paid the most, $45,156. It also lists 30 research payments totaling $22,080 from 2017 to 2025, naming 1 clinical trial.

Dmand AI lists 5 awards for Dr. Cloughesy, most recently America's Top Doctors in 2014.

Dr. Cloughesy graduated from Tulane School of Medicine in 1987.

Dr. Cloughesy is in network with 15 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.